Common Stock SEC Reporting - Current
Verified Company Profile 4/28/2017
Contact Info
  • 100 South Ashley Drive
  • Suite 600
  • Tampa, FL 33602

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0000109657
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: FL, USA
Year of Inc. Not Available
Employees 2 a/o Jan 14, 2015
Company Officers/Contacts
Anthony Cataldo CEO
Steven W. Weldon CFO
Company Directors
Anthony Cataldo Chairman
Steven W. Weldon
Service Providers
Accounting/Auditing Firm
Seligson & Giannattasio, LLP
726 N Broadway
White Plains, NY, 10603
United States
Securities Counsel
Gary R Henrie - Attorney at Law
486 W 1360 N
American Fork, UT, 84003
United States
Investor Relations Firm

Not Available
Company History
  • Formerly=DDI Pharmaceuticals, Inc. until 9-94
  • Note=2-74 State of incorporation California changed to Delaware
OXIS Security Details
Share Structure
Market Value1 $9,116,929 a/o Aug 18, 2017
Authorized Shares 150,000,000 a/o Sep 30, 2016
Outstanding Shares 144,713,162 a/o Apr 28, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Shareholders of Record 1,330 a/o Mar 30, 2016
Short Selling Data
Short Interest 32,669 (-44.88%)
Jul 31, 2017
Significant Failures to Deliver Yes - Reg SHO

1Market Value calculated only for respective security